Contineum Therapeutics (CTNM) Payables (2023 - 2025)
Historic Payables for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $786000.0.
- Contineum Therapeutics' Payables fell 4373.66% to $786000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $786000.0, marking a year-over-year decrease of 4373.66%. This contributed to the annual value of $1.8 million for FY2024, which is 18519.69% up from last year.
- As of Q3 2025, Contineum Therapeutics' Payables stood at $786000.0, which was down 4373.66% from $2.0 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Payables registered a high of $3.6 million during Q1 2025, and its lowest value of $570000.0 during Q1 2024.
- In the last 3 years, Contineum Therapeutics' Payables had a median value of $1.1 million in 2024 and averaged $1.4 million.
- The largest annual percentage gain for Contineum Therapeutics' Payables in the last 5 years was 53947.37% (2025), contrasted with its biggest fall of 4373.66% (2025).
- Over the past 3 years, Contineum Therapeutics' Payables (Quarter) stood at $635000.0 in 2023, then skyrocketed by 185.2% to $1.8 million in 2024, then plummeted by 56.6% to $786000.0 in 2025.
- Its Payables was $786000.0 in Q3 2025, compared to $2.0 million in Q2 2025 and $3.6 million in Q1 2025.